首页> 外文期刊>Genome Medicine >In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers
【24h】

In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers

机译:对HLA与药物性肝损伤的关联进行计算机分析:使用来自健康志愿者的HLA基因分型的DNA档案

获取原文
获取外文期刊封面目录资料

摘要

Background Drug-induced liver injury (DILI) is one of the most common adverse reactions leading to product withdrawal post-marketing. Recently, genome-wide association studies have identified a number of human leukocyte antigen (HLA) alleles associated with DILI; however, the cellular and chemical mechanisms are not fully understood. Methods To study these mechanisms, we established an HLA-typed cell archive from 400 healthy volunteers. In addition, we utilized HLA genotype data from more than four million individuals from publicly accessible repositories such as the Allele Frequency Net Database, Major Histocompatibility Complex Database and Immune Epitope Database to study the HLA alleles associated with DILI. We utilized novel in silico strategies to examine HLA haplotype relationships among the alleles associated with DILI by using bioinformatics tools such as NetMHCpan, PyPop, GraphViz, PHYLIP and TreeView. Results We demonstrated that many of the alleles that have been associated with liver injury induced by structurally diverse drugs (flucloxacillin, co-amoxiclav, ximelagatran, lapatinib, lumiracoxib) reside on common HLA haplotypes, which were present in populations of diverse ethnicity. Conclusions Our bioinformatic analysis indicates that there may be a connection between the different HLA alleles associated with DILI caused by therapeutically and structurally different drugs, possibly through peptide binding of one of the HLA alleles that defines the causal haplotype. Further functional work, together with next-generation sequencing techniques, will be needed to define the causal alleles associated with DILI.
机译:背景技术药物诱发的肝损伤(DILI)是导致上市后产品撤回的最常见不良反应之一。最近,全基因组关联研究已经确定了许多与DILI相关的人类白细胞抗原(HLA)等位基因。但是,细胞和化学机制尚未完全了解。方法为了研究这些机制,我们从400名健康志愿者中建立了HLA型细胞档案。此外,我们利用来自等位基因频率网络数据库,主要组织相容性复合体数据库和免疫表位数据库等公众可访问存储库中超过400万个人的HLA基因型数据来研究与DILI相关的HLA等位基因。我们通过使用生物信息学工具,例如NetMHCpan,PyPop,GraphViz,PHYLIP和TreeView,利用新颖的计算机模拟策略检查了与DILI相关的等位基因之间的HLA单体型关系。结果我们证明,许多与结构多样的药物(氟氯西林,co-amoxiclav,ximelagatran,拉帕替尼,lumiracoxib)引起的肝损伤相关的等位基因都存在于常见的HLA单倍型中,它们存在于不同种族的人群中。结论我们的生物信息学分析表明,与DILI相关的不同HLA等位基因之间可能存在治疗和结构上不同的药物之间的联系,这可能是通过定义因果单倍型的一种HLA等位基因的肽结合引起的。需要进一步的功能工作,以及下一代测序技术,才能确定与DILI相关的因果等位基因。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号